Allarity Therapeutics Inc
ALLR1.050USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
16.92MMarket Cap
0.12P/E TTM
More Details of Allarity Therapeutics Inc Company
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. It is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Allarity Therapeutics Inc Info
Ticker SymbolALLR
Company nameAllarity Therapeutics Inc
IPO dateDec 21, 2021
CEOJensen (Thomas H)
Number of employees6
Security typeOrdinary Share
Fiscal year-endDec 21
Address24 School St., 2Nd Floor
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02108
Phone14014264664
Websitehttps://allarity.com/
Ticker SymbolALLR
IPO dateDec 21, 2021
CEOJensen (Thomas H)
Company Executives of Allarity Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Gerald W. (Jerry) Mclaughlin
Mr. Gerald W. (Jerry) Mclaughlin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jesper Hoiland
Mr. Jesper Hoiland
Independent Director
Independent Director
--
--
Dr. Steen Meier Knudsen, Ph.D.
Dr. Steen Meier Knudsen, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Laura Benjamin, Ph.D.
Dr. Laura Benjamin, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
President, Chief Development Officer
President, Chief Development Officer
--
--
Mr. Thomas H. Jensen
Mr. Thomas H. Jensen
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Gerald W. (Jerry) Mclaughlin
Mr. Gerald W. (Jerry) Mclaughlin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jesper Hoiland
Mr. Jesper Hoiland
Independent Director
Independent Director
--
--
Dr. Steen Meier Knudsen, Ph.D.
Dr. Steen Meier Knudsen, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Laura Benjamin, Ph.D.
Dr. Laura Benjamin, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
President, Chief Development Officer
President, Chief Development Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Private Advisor Group LLC
1.74%
The Vanguard Group, Inc.
1.54%
Geode Capital Management, L.L.C.
0.95%
State Street Investment Management (US)
0.86%
Citadel Advisors LLC
0.59%
Other
94.34%
Shareholders
Shareholders
Proportion
Private Advisor Group LLC
1.74%
The Vanguard Group, Inc.
1.54%
Geode Capital Management, L.L.C.
0.95%
State Street Investment Management (US)
0.86%
Citadel Advisors LLC
0.59%
Other
94.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.42%
Investment Advisor/Hedge Fund
2.01%
Hedge Fund
1.10%
Individual Investor
0.16%
Other
93.31%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
27
1.03M
2.77%
--
2025Q3
29
1.03M
3.02%
+748.30K
2025Q2
22
195.09K
1.28%
+102.73K
2025Q1
21
92.36K
0.69%
-25.09K
2024Q4
18
104.49K
0.52%
+82.62K
2024Q3
15
21.87K
0.66%
+4.85K
2024Q2
17
17.01K
0.14%
+16.94K
2024Q1
14
74.00
11.50%
-1.11K
2023Q4
24
106.00
11.88%
-1.05K
2023Q3
25
1.15K
0.18%
+1.14K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
89.80K
0.62%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
50.65K
0.35%
+16.73K
+49.32%
Jun 30, 2025
Citadel Advisors LLC
--
0%
-44.00
-100.00%
Dec 31, 2023
Graff (Jeremy R.)
24.88K
0.17%
+24.88K
--
Sep 30, 2025
Two Sigma Investments, LP
--
0%
-63.00
-100.00%
Mar 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 24, 2024
Merger
30→1
Jul 24, 2024
Merger
30→1
Jul 24, 2024
Merger
30→1
Jul 24, 2024
Merger
30→1
Apr 04, 2024
Merger
20→1
Apr 04, 2024
Merger
20→1
Date
Type
Ratio
Jul 24, 2024
Merger
30→1
Jul 24, 2024
Merger
30→1
Jul 24, 2024
Merger
30→1
Jul 24, 2024
Merger
30→1
Apr 04, 2024
Merger
20→1
Apr 04, 2024
Merger
20→1
Apr 04, 2024
Merger
20→1
Apr 04, 2024
Merger
20→1
Jun 27, 2023
Merger
40→1
Jun 27, 2023
Merger
40→1
View more
FAQs
Who are the top five shareholders of Allarity Therapeutics Inc?
The top five shareholders of Allarity Therapeutics Inc are:
The Vanguard Group, Inc. holds 89.80K shares, accounting for 0.62% of the total shares.
Geode Capital Management, L.L.C. holds 50.65K shares, accounting for 0.35% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Graff (Jeremy R.) holds 24.88K shares, accounting for 0.17% of the total shares.
Two Sigma Investments, LP holds 0.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 89.80K shares, accounting for 0.62% of the total shares.
Geode Capital Management, L.L.C. holds 50.65K shares, accounting for 0.35% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Graff (Jeremy R.) holds 24.88K shares, accounting for 0.17% of the total shares.
Two Sigma Investments, LP holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Allarity Therapeutics Inc?
The top three shareholder types of Allarity Therapeutics Inc are:
Private Advisor Group LLC
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Private Advisor Group LLC
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
How many institutions hold shares of Allarity Therapeutics Inc (ALLR)?
As of 2025Q4, 27 institutions hold shares of Allarity Therapeutics Inc, with a combined market value of approximately 1.03M, accounting for 2.77% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.25%.
What is the biggest source of revenue for Allarity Therapeutics Inc?
In --, the -- business generated the highest revenue for Allarity Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
